Warning: Declaration of Suffusion_MM_Walker::start_el($output, $item, $depth, $args) should be compatible with Walker_Nav_Menu::start_el(&$output, $item, $depth = 0, $args = Array, $id = 0) in /home/hygiol5/public_html/wp-content/themes/suffusion/library/suffusion-walkers.php on line 39
Dec 082013
 

The Hygiology Post ®  is presenting information about a company that seems to have much potential to help many people. Both 2012 and 2013 appear to be pivotal years in determining how helpful the patented technologies may actually be for people. Senesco Technologies has continued to update information on its web site. As a matter of disclosure : The author continues to be a current shareholder in the company.

A recent article on the Senesco Technologies web site (https://senesco.com/newsitem.php?id=288; obtained on 12-7-13) began the following way:

“12/4/2013

Completion of Cohort 3 in Phase 1b/2a Study in Multiple Myeloma and Non-Hodgkins B-Cell Lymphoma Data Review Committee Approves Dose Escalation to Cohort 4

BRIDGEWATER, N.J. (December 4, 2013) – Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC QB: SNTI) reported today the completion of cohort 3 of its Phase 1b/2a clinical trial for its drug, SNS01-T, for the treatment of multiple myeloma and lymphoma. The Company has also received approval from its Data Review Committee to proceed to cohort 4, which is expected to require six evaluable patients. The Data Review Committee’s review of the results of cohort 3 concluded that SNS01-T was safe and well tolerated at a dose of 0.2 mg/Kg. No drug-related serious adverse events or dose limiting toxicities have been observed in the study. The patients in cohort 4 will be receiving 0.375 mg/Kg of SNS01-T.

‘We are excited to start cohort 4 in our clinical trial at almost twice the dose level of cohort 3. The 0.375 mg/Kg dose is the dose that produced the strongest effect in the pre-clinical cancer models of myeloma and lymphoma,’ stated Leslie J. Browne, Ph.D., President and CEO of Senesco. ‘We are also pleased that in addition to announcing the results of cohort 3 via press release, they will also be presented on Saturday, December 7, 2013 during the evening poster session at the 55th American Society of Hematology Annual Meeting in New Orleans.’ ”

 

The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.

 

Louis DeCola, Jr.  © 2013                                    The Hygiology Post ®